Colonial Penn Center
3641 Locust Walk
Philadelphia, PA 19104
Links: CV
Alex Sapir, a thirty-year commercial executive of the pharmaceutical and biotech industry, most recently served as the CEO of ReViral, a venture-backed biotech company focused on anti-viral drug development, until the company was acquired by Pfizer in June 2022. Prior to ReViral, Alex was the President and CEO at Dova Pharmaceuticals joining as employee #1 in December 2017. Over a 24-month period, the company transformed to a 150-person fully integrated, revenue generating, publicly-traded biotech company. In November 2019, Dova was acquired by Swedish Orphan Biovitrum AB (SOBI) for $900M. Prior to Dova, Alex spent 10 years (2006-2016) at United Therapeutics as the Executive Vice President for Marketing and Sales.
Prior to his career in biotech, Alex worked at ZS Associates and GlaxoSmithKline. He earned an M.B.A. from Harvard Business School and a B.A. in Economics from Franklin and Marshall College.
Alex currently serves on the Board of Directors for PhaseBio, a publicly-traded biotechnology company, and is a frequent guest lecturer at Duke University’s Fuqua School of Business where he leads case study discussions related to pharmaceutical marketing strategy.
This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.
HCMG8630001 ( Syllabus )
This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.
HCMG2150001 ( Syllabus )
This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.
This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.
Arranged with members of the Faculty of the Health Care Systems Department. For further information contact the Department office, Room 204, Colonial Penn Center, 3641 Locust Walk, 898-6861.
Experts from Wharton and Penn Engineering outline a framework for transforming ESG from a corporate obligation to an innovation engine for growth that can benefit all stakeholders.…Read More
Knowledge @ Wharton - 3/13/2023Wharton’s David Erickson explains the current challenges facing the private equity market and potential ways to overcome them.…Read More
Knowledge @ Wharton - 3/13/2023Politicians and corporate America are clashing over stock buybacks. Here are the facts, according to Wharton’s Michael Roberts.…Read More
Knowledge @ Wharton - 3/7/2023